Havas Lynx Expands New York Leadership with Claire Knapp and Bruno Rebelo
Havas Lynx has announced Claire Knapp, CEO of Havas Lynx UK, will expand her leadership remit to oversee Havas Lynx New York. The agency also appointed Bruno Rebelo as chief creative officer, New York, further strengthening the agency's New York leadership team as it continues to build on its position as one of the world's leading healthcare communications networks.
Claire has spent more than 15 years at Havas Lynx, pioneering the agency's strategic offerings, and has held a series of leadership roles spanning strategy, innovation, client partnership and business growth. Throughout her career, she has led global, regional and local initiatives across creative and media disciplines, helping shape work across multiple therapeutic areas and advancing internationally recognised thought leadership on healthcare professional wellbeing, health misinformation, sustainability and patient-centricity. As part of her expanded remit, Claire will be based in New York while dividing her time between the US and UK.
With her expanded remit, Claire leads a 700-strong organisation across Manchester, London and New York, championing Havas Lynx's vision to deliver impact that matters through the integration of creativity and science. Under her leadership, the agency continues to evolve its capabilities across data, AI, customer experience, creator engagement and localisation while maintaining its reputation as one of the industry's most awarded healthcare agencies.
"Claire has played an instrumental role in shaping Havas Lynx into one of the most respected healthcare communications businesses in the industry," said Dan Rubin, group president, North America, Havas Health Network. "Her strategic vision, entrepreneurial mindset and commitment to leveraging creativity to deliver impact that matters have helped drive the agency's evolution, growth and reputation for excellence. Claire's leadership, coupled with her passion for innovation and talent development, positions Havas Lynx strongly for its next chapter."
"Healthcare continues to evolve at an incredible pace, creating new opportunities for creativity, innovation and connection," said Claire. "I’m excited to build on the strong foundation we’ve created and, alongside Bruno and our teams around the world, bring the hearts, minds and teeth that define Havas Lynx to helping clients navigate what’s next and deliver impact that matters.”
Joining Havas, Bruno brings more than two decades of experience across healthcare, pharmaceutical and consumer marketing. Most recently chief creative officer at Grey Health New York, he has established himself as one of the industry's most recognised creative leaders, with work honoured by Cannes Lions, D&AD, The One Show, Clio Awards, London International Awards, New York Festivals, Effies and other leading international award programs.
Prior to joining Havas Lynx, Bruno played a key role in building award-winning creative organisations and fostering cultures centred on innovation, craft and creative excellence. His experience spans disease awareness, oncology, mental health, rare diseases and consumer health, and he is widely respected for championing ideas that create meaningful impact for both brands and the people they serve.
"Bruno is one of the most accomplished and respected creative leaders in healthcare today," said Eric Weisberg, global chief creative officer, Havas Health Network. “His work demonstrates that healthcare advertising can shape culture, drive innovation, and lead the industry in creativity. Bruno brings a rare combination of bold thinking, exceptional craft and deep category expertise, and I’m excited to see how his vision helps drive impact that matters for the brands at Havas Lynx New York.”
"Havas Lynx has built an extraordinary reputation for combining scientific rigor with world-class creativity," said Bruno. "I'm excited to join the team at a moment of tremendous momentum and help shape the next generation of work that delivers meaningful impact for clients, communities and patients alike."
